Finance

Beta
Lists
NAMS:NASDAQ
NewAmsterdam Pharma Company NV
$29.96
-3.20%
(-0.99) 1D
Jun 9, 12:49:31 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NAMS...
Open
$31.46
High
$32.04
Low
$29.61
Mkt. cap
3.48B
Avg. vol.
1.54M
Volume
294.90K
52-wk high
$42.20
52-wk low
$17.63
EPS
-$1.77
Beta
0.08
Shares outstanding
116.90M
No. of employees
100
Open
$31.46
High
$32.04
Low
$29.61
Mkt. cap
3.48B
Avg. vol.
1.54M
Volume
294.90K
52-wk high
$42.20
52-wk low
$17.63
EPS
-$1.77
Beta
0.08
Shares outstanding
116.90M
No. of employees
100
Analyst outlook
Analyst Ratings
Based on 10 analysts giving stock ratings to NAMS in the past 3 months
Strong Buy
Buy
9
Hold
1
Sell
0
12 month forecast
Based on 10 Wall Street analysts offering 12 month price targets for NAMS in the last 3 months.
Highest
Current $29.96
$60.00 (+100.27%)
Average
$47.86 (+59.75%)
Lowest
$38.00 (+26.84%)
News stories
From sources across the web
About NewAmsterdam Pharma Company NV
CEO-
Employees100
Founded2019
Headquarters-
SectorBiotechnology
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
19.14M
348.00K
32.00K
3.04M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
27.52M
30.97M
38.59M
38.01M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.26M
24.52M
27.42M
23.45M
Operating expense
54.78M
55.49M
66.01M
61.46M
Total operating expenses
54.78M
55.49M
66.01M
61.46M
Operating income
-35.64M
-55.14M
-65.98M
-58.42M
Other non operating income
2.59M
-23.79M
-15.34M
5.94M
EBT including unusual items
-17.36M
-72.00M
-74.92M
-48.44M
EBT excluding unusual items
-17.36M
-72.00M
-74.92M
-48.44M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17.36M
-72.00M
-74.92M
-48.44M
Net profit margin
-90.70%
-20,691.09%
-234,134.38%
-1,593.45%
Earnings per share
-
-
-
-
Interest and investment income
7.06M
6.71M
6.47M
5.65M
Interest expense
-
-
-
-
Net interest expenses
7.06M
6.71M
6.47M
5.65M
Depreciation and amortization charges
-
-
-
-
EBITDA
-35.59M
-55.08M
-65.92M
-58.36M
Gain or loss from assets sale
-
1.00K
11.00K
12.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more